Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in Patients With Normal ALT

NCT ID: NCT00230477

Last Updated: 2007-11-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 19 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2003-04-30
• Study Completion Date: 2007-08-31

Brief Summary

This project is a randomized, open-label trial of adefovir dipivoxil (Hepsera) and lamivudine combination therapy versus adefovir dipivoxil (Hepsera) monotherapy. Both adefovir dipivoxil and lamivudine are nucleoside analogues approved by the U.S. FDA for the treatment of chronic hepatitis B.

The primary hypothesis is that subjects treated with combination therapy will see their viral DNA count decrease in an amount greater than subjects treated with monotherapy. The secondary hypothesis is that subjects treated with combination therapy will have a higher HBeAg conversion rate compared to historical controls of subjects treated with lamivudine or adefovir dipivoxil monotherapy.

Conditions

Hepatitis B

Keywords

Hepatitis B

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Mono therapy

Hepsera

Group Type: ACTIVE_COMPARATOR

Hepsera

Intervention Type: DRUG

Combo therapy

Group Type: ACTIVE_COMPARATOR

Hepsera and lamivudine

Intervention Type: DRUG

Interventions

Hepsera

Intervention Type: DRUG

Hepsera and lamivudine

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• older than 18 years
• HBsAg+ at screening and for at least 6 months prior to study entry
• HBeAg+
• HBV DNA greater than 6 log10 copies/mL
• Platelet count greater than 50,000 platelets/mm3
• Hemoglobin greater than 7.5 g/dL
• ALT less than ULN
• Estimated creatine clearance>50 mL/min as estimated by the Crockcroft-Gault equation ((140-age) x (kg)/(serum creatine x 72) (for women x 0.85))
• Female and male participants must be practicing an effective form of contraception (male or female condom with spermicide, diaphragm or cervical cap with spermicide, intrauterine device, hormonal contraception)
• Serum alpha-fetoprotein less than 50 ng/mL within 30 days of study entry
• Childs-Pugh score less than 7 and no ascites, variceal bleeding, or hepatic encephalopathy
• able to give written informed consent and to comply with the study protocol

Exclusion Criteria

• history or evidence of HIV, hepatitis C or hepatitis D
• known or suspected hypersensitivity to adefovir or other nucleoside/nucleotide analogs.
• history of clinically significant renal dysfunction
• any active medical or psychiatric illness that, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance with the protocol
• pregnancy or breastfeeding
• receipt of systemic corticosteroids within 90 days of study entry
• receipt of nephrotoxic drugs within 8 weeks prior to study screening or expected use of these agents during the course of the study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Gilead Sciences

INDUSTRY

Sponsor Role: collaborator

GlaxoSmithKline

INDUSTRY

Sponsor Role: collaborator

University of Washington

OTHER

Sponsor Role: lead

Principal Investigators

John D Scott, MD, MS

Role: PRINCIPAL_INVESTIGATOR

University of Washington

Locations

Harborview Medical Center

Seattle, Washington, United States

Countries

United States

Other Identifiers

03-5944-A03

Identifier Type: -

Identifier Source: org_study_id